Healios K.K (TYO:4593) said it made progress on its application for conditional approval of its MultiStem ARDS treatment in Japan after agreeing with regulators on manufacturing details, according to a Thursday filing on the Tokyo Stock Exchange.
Clinical aspects of the application will be discussed with regulators in mid-January 2025.
Price (JPY): $167.00, Change: $+3.0, Percent Change: +1.83%